Alogliptin Dosing in Renal Impairment
For patients with type 2 diabetes and impaired renal function, alogliptin requires dose reduction based on creatinine clearance: 25 mg daily for normal renal function (CrCl ≥60 mL/min), 12.5 mg daily for moderate impairment (CrCl 30-59 mL/min), and 6.25 mg daily for severe impairment or end-stage renal disease (CrCl <30 mL/min). 1
Standard Dosing by Renal Function
The FDA-approved dosing regimen for alogliptin is straightforward and based on creatinine clearance 1:
- Normal renal function (CrCl ≥60 mL/min): 25 mg once daily - no dose adjustment needed 1
- Moderate renal impairment (CrCl 30 to <60 mL/min): 12.5 mg once daily 1
- Severe renal impairment (CrCl 15 to <30 mL/min): 6.25 mg once daily 1
- End-stage renal disease (CrCl <15 mL/min or requiring hemodialysis): 6.25 mg once daily 1
Alogliptin may be administered without regard to the timing of dialysis in patients on hemodialysis 1. The drug can be taken with or without food 1.
Important Clinical Considerations
Assessment of renal function is required prior to initiating alogliptin and periodically thereafter to ensure appropriate dose adjustments 1. This is critical because alogliptin is primarily eliminated through the kidneys, with 60.8-63.4% excreted renally 2.
Cardiovascular Safety Concerns
While alogliptin demonstrated cardiovascular safety in the EXAMINE trial showing non-inferiority versus placebo in type 2 diabetic patients following acute coronary syndrome 3, the FDA issued a warning in April 2016 that alogliptin may increase the risk for heart failure, especially in patients with preexisting heart failure or renal impairment 4. This requires particular caution when prescribing to patients with cardiac disease 5.
Positioning in Treatment Algorithm
Current guidelines do not prioritize DPP-4 inhibitors like alogliptin as first-line agents for patients with chronic kidney disease 6. For patients with type 2 diabetes and CKD (eGFR <60 mL/min/1.73 m²), SGLT2 inhibitors with proven kidney or cardiovascular benefit are recommended as preferred agents 6. A GLP-1 receptor agonist with proven cardiovascular benefit is recommended for patients who do not meet glycemic targets with metformin and/or an SGLT2i, or who cannot use these drugs 6.
Comparison with Other DPP-4 Inhibitors
Unlike linagliptin, which requires no dose adjustment regardless of renal function 5, 7, alogliptin necessitates dose reduction in renal impairment 1. Sitagliptin similarly requires dose adjustments when eGFR is <45 mL/min/1.73 m², with specific dosing of 50 mg daily for moderate impairment and 25 mg daily for severe impairment 5.
Common Pitfalls to Avoid
- Failure to assess renal function before initiating therapy - this is mandatory per FDA labeling 1
- Not monitoring renal function periodically - dose adjustments may be needed as kidney function changes 1
- Using standard 25 mg dose in patients with any degree of renal impairment - this leads to drug accumulation 1
- Prescribing to patients with heart failure without careful consideration - alogliptin carries an FDA warning for increased heart failure risk 4
- Choosing alogliptin over SGLT2 inhibitors or GLP-1 RAs in patients with established cardiovascular disease or CKD - these agents have proven cardiovascular and renal benefits that alogliptin lacks 6, 5